Chemistry:Paltusotine
From HandWiki
Short description: Chemical compound
 | This article provides insufficient context for those unfamiliar with the subject. (November 2023) (Learn how and when to remove this template message) |
}}
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H22F2N4O |
| Molar mass | 456.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Paltusotine is a selective somatostatin receptor type 2 (SST2) agonist in development for the treatment of acromegaly and certain neuroendocrine tumors. It is a small molecule delivered orally.[1][2][3][4]
References
- ↑ Madan, Ajay; Markison, Stacy; Betz, Stephen F.; Krasner, Alan; Luo, Rosa; Jochelson, Theresa; Lickliter, Jason; Struthers, R. Scott (April 2022). "Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers". Pituitary 25 (2): 328–339. doi:10.1007/s11102-021-01201-z. PMID 35000098.
- ↑ Zhao, Jian; Wang, Shimiao; Markison, Stacy; Kim, Sun Hee; Han, Sangdon; Chen, Mi; Kusnetzow, Ana Karin; Rico-Bautista, Elizabeth et al. (12 January 2023). "Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist". ACS Medicinal Chemistry Letters 14 (1): 66–74. doi:10.1021/acsmedchemlett.2c00431. PMID 36655128.
- ↑ Gadelha, Monica R; Gordon, Murray B; Doknic, Mirjana; Mezősi, Emese; Tóth, Miklós; Randeva, Harpal; Marmon, Tonya; Jochelson, Theresa et al. (13 April 2023). "ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly". The Journal of Clinical Endocrinology & Metabolism 108 (5): e148–e159. doi:10.1210/clinem/dgac643. PMID 36353760.
- ↑ Zhao, Jie; Fu, Hong; Yu, Jingjing; Hong, Weiqi; Tian, Xiaowen; Qi, Jieyu; Sun, Suyue; Zhao, Chang et al. (21 February 2023). "Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine" (in en). Nature Communications 14 (1): 962. doi:10.1038/s41467-023-36673-z. ISSN 2041-1723. PMID 36810324. Bibcode: 2023NatCo..14..962Z.
 |  |
